US 11,926,843 B2
RNA-guided nucleases and active fragments and variants thereof and methods of use
Alexandra Briner Crawley, Cary, NC (US); Rodolphe Barrangou, Raleigh, NC (US); Tyson D. Bowen, Morrisville, NC (US); Michael Coyle, Chapel Hill, NC (US); and Tedd D. Elich, Durham, NC (US)
Assigned to LifeEDIT Therapeutics, Inc., Durham, NC (US)
Filed by LifeEDIT Therapeutics, Inc., Morrisville, NC (US)
Filed on Sep. 17, 2021, as Appl. No. 17/478,374.
Application 17/478,374 is a continuation of application No. 16/432,321, filed on Jun. 5, 2019, granted, now 11,162,114.
Claims priority of provisional application 62/805,041, filed on Feb. 13, 2019.
Claims priority of provisional application 62/805,045, filed on Feb. 13, 2019.
Claims priority of provisional application 62/686,901, filed on Jun. 19, 2018.
Claims priority of provisional application 62/680,859, filed on Jun. 5, 2018.
Claims priority of provisional application 62/680,846, filed on Jun. 5, 2018.
Claims priority of provisional application 62/680,845, filed on Jun. 5, 2018.
Claims priority of provisional application 62/680,862, filed on Jun. 5, 2018.
Claims priority of provisional application 62/680,863, filed on Jun. 5, 2018.
Claims priority of provisional application 62/680,853, filed on Jun. 5, 2018.
Prior Publication US 2022/0002756 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/90 (2006.01); C12N 9/22 (2006.01); C12N 15/10 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12N 15/52 (2006.01); C12N 15/63 (2006.01)
CPC C12N 15/907 (2013.01) [C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/902 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] 28 Claims
 
1. A nucleic acid molecule comprising a polynucleotide encoding an RNA-guided nuclease (RGN) polypeptide, wherein said polynucleotide comprises a nucleotide sequence encoding an RGN polypeptide comprising an amino acid sequence:
(i) having at least 95% sequence identity to any one of SEQ ID NOs: 11, 27, 45, or 54;
(ii) having at least 98% sequence identity to SEQ ID NOs: 1 or 19; or
(iii) set forth as SEQ ID NO: 36;
wherein said polynucleotide encoding an RGN polypeptide is operably linked to a promoter heterologous to said polynucleotide.